FDA Slams Break On Fulcrum Therapeutics’ Sickle Cell Disease Study, Shares Plummet
The FDA verbally informed Fulcrum Therapeutics Inc (NASDAQ:FULC) that it has issued a full clinical hold regarding the Investigational New Drug (IND)…
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
Novartis AG (NYSE:NVS) has decided to terminate the Collaboration and License Agreement with Pliant Therapeutics, Inc.(NASDAQ:PLRX), announced in 2019. Novartis told…
Why Cingulate Shares Are Trading Higher Today
Cingulate Inc (NASDAQ:CING) announced positive topline results from the CTx-1301-003 study assessing the effect of food on the absorption of its…
Orchard Therapeutics Announced Long-term Results From An Updated Integrated Analysis Of 39 Patients With Metachromatic Leukodystrophy Treated With Investigational OTL-200 In The Clinical Development Program
Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years of follow-up (median 6.15 years)
Composite primary endpoint used
Why NeoGenomics Shares Are Trading Higher Today
NeoGenomics Inc (NASDAQ:NEO) reported Q4 revenues of $138.71 million, +10.3% Y/Y beating the consensus of $129.97 million but aligned with…
Evolent Health Q4 Top-Line Beats Expectation, Analyst Points To Visible Growth Outlook
Evolent Health Inc (NYSE:EVH) reported Q4 adjusted EPS of $0.10, missing the consensus of $0.16, compared to $0.08 a year…
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Blueprint Medicines Corporation (NASDAQ:BPMC) will regain global commercialization and development rights to Gavreto (pralsetinib), excluding Greater China, following a…
Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit
Sangamo Therapeutics Inc (NASDAQ:SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR…
4D Molecular Discloses Updated Data From Currently Paused Fabry Disease Cardiomyopathy Study
4D Molecular Therapeutics Inc (NASDAQ:FDMT) announced updated interim safety and efficacy data from the two 4D-310 INGLAXA Phase 1/2 trials for…